<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:05:23Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5494519" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5494519</identifier><datestamp>2017-07-05</datestamp><setSpec>emmolmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1757-4684</journal-id>
      <journal-id journal-id-type="publisher-id">EMMM</journal-id>
      <journal-id journal-id-type="hwp">embomm</journal-id>
      <journal-title-group>
        <journal-title>EMBO Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1757-4676</issn>
      <issn pub-type="epub">1757-4684</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5494519</article-id>
      <article-id pub-id-type="pmcid">PMC5494519</article-id>
      <article-id pub-id-type="pmc-uid">5494519</article-id>
      <article-id pub-id-type="pmid">28554942</article-id>
      <article-id pub-id-type="doi">10.15252/emmm.201607058</article-id>
      <article-id pub-id-type="publisher-id">EMMM201607058</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<styled-content style="fixed-case">MSTO</styled-content>1 is a cytoplasmic proâmitochondrial fusion protein, whose mutation induces myopathy and ataxia in humans</article-title>
        <alt-title alt-title-type="left-running-head">Aniko Gal <italic>etÂ al</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="emmm201607058-cr-0001" contrib-type="author">
          <name>
            <surname>Gal</surname>
            <given-names>Aniko</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201607058-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0002" contrib-type="author">
          <name>
            <surname>Balicza</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0003" contrib-type="author">
          <name>
            <surname>Weaver</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0004" contrib-type="author">
          <name>
            <surname>Naghdi</surname>
            <given-names>Shamim</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0005" contrib-type="author">
          <name>
            <surname>Joseph</surname>
            <given-names>Suresh K</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0006" contrib-type="author">
          <name>
            <surname>VÃ¡rnai</surname>
            <given-names>PÃ©ter</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0007" contrib-type="author">
          <name>
            <surname>Gyuris</surname>
            <given-names>Tibor</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0008" contrib-type="author">
          <name>
            <surname>HorvÃ¡th</surname>
            <given-names>Attila</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0009" contrib-type="author">
          <name>
            <surname>Nagy</surname>
            <given-names>Laszlo</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0010" contrib-type="author">
          <name>
            <surname>Seifert</surname>
            <given-names>Erin L</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0011" contrib-type="author">
          <name>
            <surname>Molnar</surname>
            <given-names>Maria Judit</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201607058-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201607058-cr-0012" contrib-type="author" corresp="yes">
          <name>
            <surname>HajnÃ³czky</surname>
            <given-names>GyÃ¶rgy</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3813-2570</contrib-id>
          <address>
            <email>gyorgy.hajnoczky@jefferson.edu</email>
          </address>
          <xref ref-type="aff" rid="emmm201607058-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="emmm201607058-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">MitoCare Center for Mitochondrial Imaging Research and Diagnostics</named-content>
        <named-content content-type="organisation-division">Department of Pathology, Anatomy and Cell Biology</named-content>
        <institution>Thomas Jefferson University</institution>
        <named-content content-type="city">Philadelphia</named-content>
        <named-content content-type="country-part">PA</named-content>
        <country country="US">USA</country>
      </aff>
      <aff id="emmm201607058-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Institute of Genomic Medicine and Rare Disorders</named-content>
        <institution>Semmelweis University</institution>
        <named-content content-type="city">Budapest</named-content>
        <country country="HU">Hungary</country>
      </aff>
      <aff id="emmm201607058-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Physiology</named-content>
        <institution>Semmelweis University</institution>
        <named-content content-type="city">Budapest</named-content>
        <country country="HU">Hungary</country>
      </aff>
      <aff id="emmm201607058-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Biochemistry and Molecular Biology</named-content>
        <institution>University of Debrecen</institution>
        <named-content content-type="city">Debrecen</named-content>
        <country country="HU">Hungary</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Corresponding author. Tel: +1Â 215Â 503Â 1427; Eâmail: <email>gyorgy.hajnoczky@jefferson.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>5</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2017</year>
      </pub-date>
      <volume>9</volume>
      <issue>7</issue>
      <issue-id pub-id-type="doi">10.1002/emmm.v9.7</issue-id>
      <fpage>967</fpage>
      <lpage>984</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>13</day>
          <month>4</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>4</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 EMBO <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2017 The Authors. Published under the terms of the CC BY 4.0 license</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EMMM-9-967.pdf"/>
      <abstract id="emmm201607058-abs-0001">
        <title>Abstract</title>
        <p>The protein <styled-content style="fixed-case">MSTO</styled-content>1 has been localized to mitochondria and linked to mitochondrial morphology, but its specific role has remained unclear. We identified a c.22GÂ &gt;Â A (p.Val8Met) mutation of <styled-content style="fixed-case">MSTO</styled-content>1 in patients with minor physical abnormalities, myopathy, ataxia, and neurodevelopmental impairments. Lactate stress test and myopathological results suggest mitochondrial dysfunction. In patient fibroblasts, <styled-content style="fixed-case">MSTO</styled-content>1 <styled-content style="fixed-case">mRNA</styled-content> and protein abundance are decreased, mitochondria display fragmentation, aggregation, and decreased network continuity and fusion activity. These characteristics can be reversed by genetic rescue. Shortâterm silencing of <styled-content style="fixed-case">MSTO</styled-content>1 in HeLa cells reproduced the impairment of mitochondrial morphology and dynamics observed in the fibroblasts without damaging bioenergetics. At variance with a previous report, we find <styled-content style="fixed-case">MSTO</styled-content>1 to be localized in the cytoplasmic area with limited colocalization with mitochondria. <styled-content style="fixed-case">MSTO</styled-content>1 interacts with the fusion machinery as a soluble factor at the cytoplasmâmitochondrial outer membrane interface. After plasma membrane permeabilization, <styled-content style="fixed-case">MSTO</styled-content>1 is released from the cells. Thus, an <styled-content style="fixed-case">MSTO</styled-content>1 lossâofâfunction mutation is associated with a human disorder showing mitochondrial involvement. <styled-content style="fixed-case">MSTO</styled-content>1 likely has a physiologically relevant role in mitochondrial morphogenesis by supporting mitochondrial fusion.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="emmm201607058-kwd-0001">misato</kwd>
        <kwd id="emmm201607058-kwd-0002">mitochondria</kwd>
        <kwd id="emmm201607058-kwd-0003">mitochondrial disease</kwd>
        <kwd id="emmm201607058-kwd-0004">mitochondrial fusion</kwd>
        <kwd id="emmm201607058-kwd-0005"><styled-content style="fixed-case">MSTO</styled-content>1</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Genetics, Gene Therapy &amp; Genetic Disease</kwd>
        <kwd>Metabolism</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Hungarian Brain Research Program</funding-source>
          <award-id>KTIA_13_NAPâAâIII/6</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Schizo2010 Consortium</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>HAESF Senior Leadership Program Fellowship</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</funding-source>
          <award-id>DK51525</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="11"/>
        <table-count count="0"/>
        <page-count count="18"/>
        <word-count count="10759"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>emmm201607058</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>July 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.2 mode:remove_FC converted:03.07.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="emmm201607058-cit-1001">
<source>EMBO Mol Med</source> (<year>2017</year>) <volume>9</volume>: <fpage>967</fpage>â<lpage>984</lpage>
</mixed-citation>
</p>
    </notes>
  </front>
  <body>
    <sec id="emmm201607058-sec-0001">
      <title>Introduction</title>
      <p>Mitochondria are highly dynamic organelles whose morphology, distribution, and activity are dependent on fusion and fission (Chan, <xref rid="emmm201607058-bib-0002" ref-type="ref">2006</xref>). Several neurodegenerative diseases such as optic atrophy, CharcotâMarieâTooth, Alzheimer's, Parkinson, and Huntington disease are associated with alterations of mitochondrial dynamics (Chan, <xref rid="emmm201607058-bib-0002" ref-type="ref">2006</xref>; Itoh <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0009" ref-type="ref">2013</xref>).</p>
      <p>MSTO1 (Misato) is an evolutionarily conserved nuclear DNAâencoded protein showing some structural similarity to eukaryotic tubulins and prokaryotic FtsZ. Null mutations of the <italic>misato</italic> in <italic>Drosophila</italic> are associated with irregular chromosomal segregation (Miklos <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0016" ref-type="ref">1997</xref>; Gurvitz <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0008" ref-type="ref">2002</xref>; MottierâPavie <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0018" ref-type="ref">2011</xref>). However, depletion of MSTO1 by siRNA was also linked to mitochondrial fragmentation and cell death, and overexpressed EGFPâMisato was localized in the mitochondria and was shown to induce aggregation of mitochondria at the perinuclear region and cell death in HeLa cells (Kimura &amp; Okano, <xref rid="emmm201607058-bib-0010" ref-type="ref">2007</xref>). In this study, MSTO1 was proposed to contribute to the cell's health as an outer mitochondrial membrane (OMM) resident affecting mitochondrial morphology. However, the mechanism by which MSTO1 supports mitochondrial morphogenesis and its potential human disease relevance remains elusive.</p>
      <p>Disorders with primary mitochondrial dysfunction are clinically heterogeneous disorders that can manifest at any age, and can affect multiple tissues and organs, commonly the most energy demanding tissues, such as the central nervous system, skeletal and cardiac muscle, liver, endocrine glands, kidney, and the eyes. Mitochondrial diseases can result from mutations of genes located in either the nuclear DNA or the maternally inherited mitochondrial DNA. Until now, based on the relevant databases (Mitomap, MitoMiner, NCBI, Nexprot), approximately 300 different mtDNA pathogenic mutations have been found. The collection of nuclear genes encoding mitochondrial proteins is still changing, and only a few hundred diseaseâassociated mutations of these genes have been identified. The minimum prevalence of all mitochondrial disorders is 1:2,000 (Suomalainen, <xref rid="emmm201607058-bib-0026" ref-type="ref">2015</xref>), but with the recent progress in identification of the mitochondrial proteins and the progress in genetic diagnosis, the number of human diseaseâassociated mutations is expected to steeply increase.</p>
      <p>In this study, we have identified an MSTO1 mutation in patients by wholeâexome sequencing. This mutation segregated in the affected family and is absent in the other sequenced cases. Members of the affected family showed a diverse collection of the following alterations: severe myopathy, hypoacusis, endocrine dysfunctions, and psychiatric symptoms. These symptoms and laboratory tests indicate a possible role for the newly found <italic>MSTO1</italic> mutation in the background of mitochondrial disorders. Therefore, we have investigated mitochondrial dynamics and bioenergetics in both patientâderived cells and cell lines using genetic rescue and gene silencing, respectively. Collectively, our studies suggest that MSTO1 is a cytoplasmic protein required for mitochondrial fusion and network formation and its loss likely causes a multisystem disorder.</p>
    </sec>
    <sec id="emmm201607058-sec-0002">
      <title>Results</title>
      <sec id="emmm201607058-sec-0003">
        <title>Clinical data</title>
        <sec id="emmm201607058-sec-0004">
          <title>Patient 1 (I/1) (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>A)</title>
          <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0001" orientation="portrait" position="float">
            <label>Figure 1</label>
            <caption>
              <title>Clinical and genetic data of the patient</title>
              <p>
<list list-type="alpha-upper" id="emmm201607058-list-0002"><list-item><p>Family tree of the investigated patients. Arrow indicates the proband.</p></list-item><list-item><p>Electron microscopy sections of the patient muscle biopsy specimen. Increased number of mitochondria both subsarcolemmal and intermyofibrillar, lipid droplets, and glycogen accumulation (electron microscopy, 30,000Ã).</p></list-item><list-item><p>Sequenogram of the suspected pathogenic mutation and the neighboring polymorphism in exon 1 of <italic>MSTO1</italic> gene from genomic (upper part) and cDNA (lower part). Arrow indicates the position of the mutation.</p></list-item><list-item><p>Taxonomical alignments of the affected MSTO1 protein sequence. Location of the alterations in the patients are shown in bold. The red âMâ indicates the amino acid substitution segregated in all affected family members.</p></list-item><list-item><p>Normalized mRNA expression level from the patient primary fibroblasts (percentage of the average value of the healthy controls) (meanÂ Â±Â SEM).</p></list-item><list-item><p>MSTO1 Western blotting of the patient and control fibroblast. Left: representative blots; right: normalized protein abundance of the percentage of the average protein expression levels of the controls (meanÂ Â±Â SEM).</p></list-item></list>
</p>
              <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
            </caption>
            <graphic id="nlm-graphic-5" xlink:href="EMMM-9-967-g002"/>
          </fig>
          <p>A 53âyearâold Hungarian female patient's symptoms started at the age of 38 with myalgia, weakness of the small hand muscles, and cognitive dysfunction. She was born as an immature, small baby from an overdue pregnancy. Her III digit on the foot was absent. Her motor and verbal development was delayed. Her bone age was also delayed. She had joint hyperlaxity and generalized lipomatosis. Presently, she has hyperthyroidism; mitral and tricuspidal insufficiency. Neurological examination revealed short stature (150Â cm), micrognathia with small closeâset eyes, myopia, myopathic face, bilateral hypoacusis, moderate atrophy of the small muscles of the hands and feet, pes varus. She had mild weakness in the distal muscles of the extremities. Deep tendon reflexes were decreased; pyramidal tract signs were not present. She had distal type hypaesthesia in the limbs. Mild truncal and upper limb ataxia and dysdiadochokinesis were present. She had anxiety and depressed mood.</p>
          <p>Her brain MRI detected frontal atrophy and enlarged interhemispheric fissure and EMG showed myopathy. CK was in normal range. The resting serum lactate level was normal, while the lactate stress test indicated altered aerobic metabolism (resting lactate: 1.7Â mmol/l (normal range: 1.0â2.0Â mmol/l), after 15Â min bicycling 0Â min: 6.5Â mmol/l, 5Â min: 4.8Â mmol/l, 15Â min: 4.2Â mmol/l, 30Â min: 3.5Â mmol/l (normal if the lactate level after 30Â min exercise is less than twofold of the resting value)). Decreased vitamin D3 was measured (13.0Â ng/ml, normal range 23.0â60.0Â ng/ml). Using light microscopy, the myopathological investigations detected moderate muscle fiber caliber variation. No ragged blue or COX negative fibers were present. Electron microscopy found increased number of mitochondria and lipid droplets both in subsarcolemmal and intermyofibrillar localization. Many mitochondria had rounded shape; intramitochondrial paracrystalline inclusions were not present. Glycogen accumulation was also detected in these regions (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>B).</p>
        </sec>
        <sec id="emmm201607058-sec-0005">
          <title>Patient 2 (II/1)</title>
          <p>The 30âyearâold daughter of patient 1 (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>A) was born from breech position. She was resuscitated. She had normal development. From age 11, episodically inflammatory lipomas occurred on her body. Her psychiatric symptoms stared at age 15 with depression and hallucinations. Severe undifferentiated type of schizophrenia was diagnosed. Some years later unilateral hypoacusis developed, and she had severe episodic ataxic gait repeatedly. Hyperthyreosis, hyperprolactanemia, and primer amenorrhea were detected as well. Neurological examination revealed mild weakness in the tibial anterior muscles and distal type hypaesthesia in the legs. Her CK and resting serum lactate level was in normal range. This patient did not agree to perform the lactate stress test. The vitamin D3 level was low (8.6Â ng/ml). Her brain MRI detected pituitary adenoma and mild cerebellar ectopia.</p>
        </sec>
        <sec id="emmm201607058-sec-0006">
          <title>Patient 3 (II/2)</title>
          <p>The 24âyearâold male patient was born from normal pregnancy. He had normal motor development. In his childhood, bone developmental problems were suspected based on his laboratory results (abnormal vitamin D3, calcium, phosphate, and ALP levels). The social anxiety started in the childhood. Later dyslexia, dysgraphia, dyscalculia, and learning difficulties were detected. His neurological examination revealed micrognathia, pectus excavatum, kyphoscoliosis, poor fine coordination, and slow psychomotility. CK was normal. Vitamin D3 was decreased (12.5Â ng/ml).</p>
        </sec>
        <sec id="emmm201607058-sec-0007">
          <title>Patient 4 (II/3)</title>
          <p>The 20âyearâold male patient was born as a hypotonic infant; his early development was delayed. He had a social anxiety since his early childhood and learning difficulties. Presently, he has autistic features with anxiety and impulsive behaviors. He had very long face, prominent jaw, and laxity of the knee joints. No neurological signs were found. The vitamin D3 level was low (10.8Â ng/ml).</p>
        </sec>
      </sec>
      <sec id="emmm201607058-sec-0008">
        <title>Mutation analysis</title>
        <p>Mitochondrial DNA mutation was not found in either blood or skeletal muscle samples, and single or multiple mtDNA deletions have been excluded as well.</p>
        <p>Exome capture sequencing generated ~9.4Â billion bases of sequence, and ~9.3Â billion bases were then mapped to the target regions based on SeqCap_EZ_Exome_v3 Kit. 95% of the target regions had at least 10Ã coverage. After identification of variants, we focused only on nonâsynonymous variants, splice acceptor and donor site mutations, and short, frame shift coding insertions or deletions (indel). Using GEM.app softwareÂ with autosomal dominant model after filtering out synonymous SNPs, 61 heterozygous variants remained, including 1 coding indel, 57 missense, 1 spliceâsite, 2 nonsense mutations. Further narrowing based on protein prediction scores resulted in 27 variations. We did not find any homozygous or compound heterozygous rare variants in the 1,015 genes, which were previously associated by the literature with mitochondrial function. The narrowing analysis for known mitochondrial genes filtered out 25 heterozygous (2 nonsense and 23 missense) variants. Among the rare variant filtering by the autosomal dominant inheritance model 16 genes were without any known function. Based on the literature, further seven genes were excluded because these genes are not linked to CNS involvements or mitochondrial dysfunctions. Finally, four missense mutations were validated with Sanger sequencing. Among them only the c.22 G&gt;A (p.Val8Met) substitution in <italic>MSTO1</italic> gene is segregated in all affected family members and was present in heterozygous form (<xref rid="emmm201607058-sup-0002" ref-type="supplementary-material">TableÂ EV1</xref> and FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>C). This mutation was found in urinary tract and colorectal tumors, as a somatic mutation (COSM3930426, COSM3930426) (<ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk">http://cancer.sanger.ac.uk</ext-link>); according to the Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>), the minor allele frequency is 0.003% (rs762798018), and it was absent in 1000 Genome (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org">http://www.1000genomes.org</ext-link>), NHLBI Exome Sequencing Project (ESP) (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), ClinVar (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar">http://www.ncbi.nlm.nih.gov/clinvar</ext-link>), dbGAP (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gap">http://www.ncbi.nlm.nih.gov/gap</ext-link>), and EGA (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/ega">http://www.ebi.ac.uk/ega</ext-link>) databases. Connection with any clinical phenotype has not been described, yet. The mutated part of MSTO1 protein sequence is highly conserved in mammals (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>D). This alteration was confirmed by cDNA sequencing from fibroblast as well (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>C). Other alterations of <italic>MSTO1</italic> gene were excluded by Sanger sequencing of the total coding sequence from genomic DNA and cDNA sequencing from patient derivate fibroblasts (MSTO P1, II/1 and MSTO P2, I/2). The copy number alteration was also excluded by realâtime PCR methodology.</p>
        <p>In the patientâderived primary fibroblast culture, the MSTO1 mRNA and protein expression were significantly decreased (MSTO P1 and MSTO P2) compared with the average values of three controls (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>E and F). The MSTO1 mRNA expression was 42.0Â Â±Â 3.0% in MSTO P1 and 36.3Â Â±Â 4.7% in MSTO P2 (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>E), while the protein abundance was 71.4Â Â±Â 2.3% in MSTO P1 and 61.0Â Â±Â 1.6% in MSTO P2 (FigÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref>F). The other two affected family members did not agree to the skin biopsy.</p>
      </sec>
      <sec id="emmm201607058-sec-0009">
        <title>
<italic>In silico</italic> analysis</title>
        <p>Based on the prediction of the InterPro domain software, MSTO1 protein has 2 tubulin/Ftzâlike GTPase domains. The prediction of GTP binding residues in the protein sequence by GTPâbinder application (Chauhan <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0003" ref-type="ref">2010</xref>) found seven possible GTP binding sites in the first (aa 16â21; 23â24; 30; 62â63; 73â74; 76â77; and 81) tubulin/Ftz GTPase domain (FigÂ <xref rid="emmm201607058-fig-0001ev" ref-type="fig">EV1</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="emmm201607058-fig-0001ev" orientation="portrait" position="float">
          <label>Figure EV1</label>
          <caption>
            <title>
<italic>In silico</italic> analysis of the predicted <styled-content style="fixed-case">GTP</styled-content>ase domains of <styled-content style="fixed-case">MSTO</styled-content>1</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0010"><list-item><p>Predicted GTP binding and GTPase homology domains in MSTO1. The bold font indicates the possible GTPase binding sites.</p></list-item><list-item><p>Alignment of MSTO1 with the GTPase domain of MFNs. The bold fonts and box indicates the higher similarities.</p></list-item><list-item><p>Evolutionary conservation of the region in MSTO1, which shows similarity the GTPase regions of MFNs. The bold fonts and box indicates the higher similarities.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="EMMM-9-967-g003"/>
        </fig>
        <p>The protein alignments between MSTO1 and the known mitochondrial fusion proteins detected some similarities in a 12 amino acid span with the OMM fusion proteins, MFN1 and MFN2 (FigÂ <xref rid="emmm201607058-fig-0001ev" ref-type="fig">EV1</xref>B). These amino acids are located in the second tubulin/Ftz, GTPase domain of the MSTO1 protein and are highly conserved in mammals (FigÂ <xref rid="emmm201607058-fig-0001ev" ref-type="fig">EV1</xref>C). To determine the significance of the similarity between MSTO1 and MFN1, BLAST alignments using randomly scrambled versions of each protein were performed with the default parameters for multiple sequence alignment (word size 3, BLOSUM62 matrix). Out of 100 alignments MFN1 and scrambled MSTO1s and 100 alignments of MSTO1 and scrambled MFN1s, 17 (8.5%) aligned segments with an equal or higher bitâscore were found. Thus, the homology is not statistically significant in and of itself, though we would note the strong conservation across species of the acidic amino acids in MSTO1 and mitofusins. No similarity was found between MSTO1 and the inner mitochondrial membrane (IMM) fusion protein, OPA1.</p>
      </sec>
      <sec id="emmm201607058-sec-0010">
        <title>Mitochondrial morphology in primary fibroblasts</title>
        <p>Mitochondrial morphology was visualized in fibroblasts obtained from I/2: MSTO1 Patient 1 (P1) and II/1: MSTO1 Patient 2 (P2), the 2 family members who agreed to undergo skin biopsy, and from 3 individuals serving as controls (Ctrl 1, 2, and 3), expressing mitochondrial matrixâtargeted DsRed1 (mtDsRed). The cells with various mitochondrial morphology (FigÂ <xref rid="emmm201607058-fig-0002ev" ref-type="fig">EV2</xref>A) were quantified as a percentage of the total number of transfected cells (â¥Â 20 cells per experiment, <italic>n</italic>Â =Â 5 independent experiments). More cells with aggregated mitochondria were counted in MSTO1 patient fibroblasts than in the controls (P1: 37.8%; P2: 33.3%; Ctrl average: 11.7Â Â±Â 0.4%). In patient fibroblasts, the percentage of cells with fragmented and partially fragmented mitochondria was also increased (P1, partially fragmented: 46.7%, fragmented: 17.3; P2: partly fragmented: 48.8%, fragmented: 8.5%; Ctrl average: partly fragmented: 25.1Â Â±Â 1%, fragmented: 0Â Â±Â 0%) (FigÂ <xref rid="emmm201607058-fig-0002ev" ref-type="fig">EV2</xref>AâC).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="emmm201607058-fig-0002ev" orientation="portrait" position="float">
          <label>Figure EV2</label>
          <caption>
            <title>Mitochondrial morphology in primary fibroblasts</title>
            <p>Mitochondrial morphology was scored as follows: fragmented, mainly small and round; partly fragmented, intermediate, mixture of round and shorter tubulated; normal, tubulated, long and higher interconnectivity; elongated, very long, tubulated. The percentage of cells with indicated mitochondrial morphologies was determined as a percentage of the total number of DsRedâtransfected cells counted (â¥Â 20 cells per experiment) in <italic>n</italic>Â =Â 5 independent experiments.
<list list-type="simple" id="emmm201607058-list-0011"><list-item><label>A</label><p>Representative figures of the different mitochondrial types. The arrowhead indicates the aggregated mitochondria. The white box showing higher magnifications.</p></list-item><list-item><label>B, C</label><p>Distribution of the different type of mitochondria in primary fibroblasts.</p></list-item><list-item><label>D, E</label><p>Distribution of the different type of mitochondria after MSTO1 silencing in HeLa cells (Scr.: scramble siRNAâsilenced cells; MSTO1: MSTO1 siRNAâsilenced cells).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="EMMM-9-967-g005"/>
        </fig>
      </sec>
      <sec id="emmm201607058-sec-0011">
        <title>Mitochondrial continuity in primary fibroblasts</title>
        <p>To evaluate whether the distinct mitochondrial morphology in patient and control fibroblasts can result from different levels of interorganellar continuity and fusion events, the cells were coâtransfected with cDNA encoding mtDsRed1 and mitochondrial matrixâtargeted photoactivatable GFP (mtPAâGFP). Using confocal microscopy, time series of fluorescence images were recorded and 25Â Î¼m<sup>2</sup> squareâshaped areas were illuminated by a pulsed laser to photoactivate mtPAâGFP (Eisner <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0007" ref-type="ref">2014</xref>; Weaver <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0030" ref-type="ref">2014</xref>), which is a soluble protein that shows rapid diffusion (Partikian <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0022" ref-type="ref">1998</xref>). Mitochondrial matrix continuity and connectivity is unveiled by the diffusion of the photoactivated mtPAâGFP to the regions outside the 2P illuminated area. Image time series shows that mtPAâGFP diffusion was slower in P1 than in the ageâmatched Ctrl3 fibroblasts (FigÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>A). To quantify connectivity, the time course of the ratio of <italic>F</italic>
<sub>mtPAâGFP</sub> and <italic>F</italic>
<sub>mtDsRed</sub> was calculated for the region of photoactivation (RPA) in both P1 and P2 and in the three controls (FigÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>B). At 500Â s, the lesser decay of the fluorescence ratio in the RPA indicates a decrease in the combined activity of mitochondrial network formation, mitochondrial fusion, and mitochondrial movements in the MSTO1 patient cells (FigÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>B).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>Mitochondrial continuity in primary fibroblasts</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0003"><list-item><p>Image time series showing a representative fibroblast cell before and after 2P photoactivation of mtPAâGFP (white squares): 0Â s (preâactivation), 24Â s (immediately after photoactivation), 40Â s, and 500Â s.</p></list-item><list-item><p>The time course of the ratio of <italic>F</italic>
<sub>mtPAâGFP</sub> to <italic>F</italic>
<sub>mtDsRed</sub> for the region of photoactivation (RPA) (left); the decay of the fluorescence ratio in the RPA at 500Â s (right) (number of imaged cells: Ctrl1 <italic>N</italic>Â =Â 94; Ctrl2 <italic>N</italic>Â =Â 45; Ctrl3 <italic>N</italic>Â =Â 87; MSTO P1 <italic>N</italic>Â =Â 84; MSTO P2 <italic>N</italic>Â =Â 130 from minimum three experiments per each cells). Stars indicate the significant differences (Student's <italic>t</italic>âtest: Ctrl average vs. MSTO P1 *<italic>P</italic>Â =Â 1.44Â ÃÂ 10<sup>â9</sup>, Ctrl average vs. MSTO P2 *<italic>P</italic>Â =Â 1.52Â ÃÂ 10<sup>â12</sup>; oneâway ANOVA: <italic>P</italic>Â =Â 0.00815) (meanÂ Â±Â SEM).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="EMMM-9-967-g004"/>
        </fig>
      </sec>
      <sec id="emmm201607058-sec-0012">
        <title>Mitochondrial fusion dynamics in primary fibroblasts</title>
        <p>To validate fusion events, reciprocal spreading of mtPAâGFP and mtDsRed among mitochondria that were not continuous at the time of mtPAâGFP photoactivation was sought (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>A). The fusion events were quantitatively analyzed by the progression of the distribution of mtPAâGFP fluorescence between the images collected in the first 8 min after photoactivation. The result of manual counting indicates less mitochondrial fusion activity in the MSTO1 patient fibroblasts (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>B). The total fusion numbers were decreased significantly inÂ the patient fibroblasts (P1: 4.01Â Â±Â 0.13Â fusion/run; P2: 3.50Â Â±Â 0.12Â fusion/run; Ctrl average: 6.39Â Â±Â 0.24Â fusion/run) (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>B). In a previous study, we have quantified the effect of two different ADOAâassociated OPA1 mutations on the mitochondrial fusion activity using the same manual counting method used in the present study (Eisner <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0007" ref-type="ref">2014</xref>). G300E point mutation in the GTPase domain and Î58 deletion of the GTPase domain caused 60â70% decrease in the fusion activity, whereas the present MSTO1 mutations induced an approximately 40% decrease in fusion activity. However, we have also studied an ADOAâassociated OPA1 mutation (c.984) that caused a lesser decrease in the fusion activity (30%) than the present MSTO1 mutations. Thus, the MSTO1âassociated fusion decrease is in the range of the OPA1âassociated ones.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <title>Mitochondrial fusion events in primary fibroblast</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0004"><list-item><p>Representative example is shown out of 2,200 events. During photoactivation of mtPAâGFP, mtDsRed is photobleached, allowing detection of the mixing of each fluorescent protein after mitochondrial fusion. Mitochondria shown in the white box undergo an endâtoâend fusion event at 272Â s. During the event, mitochondrion #1 donates fluorescent mtPAâGFP to mitochondrion #2 (acceptor). At the same time, the green acceptor mitochondrion donates fluorescent mtDsRed to mitochondrion #1. Arrows show the location of the fusion, abrupt, and complementary interâmitochondrial transfer of the fluorescent proteins. The graphs on the right show the average mtDsRed1 and mtPAâGFP fluorescence intensities of mitochondrion 1 and mitochondrion 2 before and after fusion event. The white box indicates two mitochondria before and after fusion.</p></list-item><list-item><p>Rates of fusion events in primary fibroblasts. Stars indicate the significant differences (Student's <italic>t</italic>âtest: Ctrl average vs. MSTO P1 *<italic>P</italic>Â =Â 9.6Â ÃÂ 10<sup>â21</sup>, Ctrl average vs. MSTO P2 *<italic>P</italic>Â =Â 5.3Â ÃÂ 10<sup>â31</sup>; oneâway ANOVA: <italic>P</italic>Â &lt;Â 0.00001) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Average duration of fusion events which were followed by fission during the 8âmin recording time (meanÂ Â±Â SEM).</p></list-item><list-item><p>Distribution of transient and complete type fusion events.</p></list-item><list-item><p>Orientation characteristics of fusion events in different fibroblasts (meanÂ Â±Â SEM).</p></list-item><list-item><p>Western blot of the main fusion and fission proteins. Left: representative blots; right: quantified protein abundances in MSTO cells relative to the control cell average (meanÂ Â±Â SEM).</p></list-item></list>Data information: (BâE) Number of fusions: Ctrl1 <italic>N</italic>Â =Â 599; Ctrl2 <italic>N</italic>Â =Â 292; Ctrl3 <italic>N</italic>Â =Â 551; MSTO P1 <italic>N</italic>Â =Â 299; MSTO P2 <italic>N</italic>Â =Â 459; number of imaged cells: Ctrl1 <italic>N</italic>Â =Â 94; Ctrl2 <italic>N</italic>Â =Â 45; Ctrl3 <italic>N</italic>Â =Â 87; MSTO P1 <italic>N</italic>Â =Â 84; MSTO P2 <italic>N</italic>Â =Â 130 from minimum three experiments per each cells.<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="EMMM-9-967-g006"/>
        </fig>
        <p>Fusion activity was also quantified by an algorithm that calculates the loss of the greenâonly pixels during the postâphotoactivation period. This unbiased determination showed that the average halfâtime of the GFPâonly pixel loss was increased significantly in the MSTO1 fibroblasts (P1: 1,914Â Â±Â 305Â s; P2: 1,817Â Â±Â 312Â s; Ctrl average: 713Â Â±Â 105Â s). Thus, results obtained by two different approaches show that mitochondrial fusion activity is suppressed in the MSTO1âdeficient patient cells.</p>
        <p>The average duration of individual fusion events was similar in both MSTO1 fibroblasts and in ageâmatched controls (P1: 133Â Â±Â 7Â s; P2: 133Â Â±Â 7Â s; Ctrl average: 117Â Â±Â 6Â s) (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>C). Furthermore, the distribution of different fusion types in terms of rapid reversal (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>D) and orientations (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>E) did not show any alterations in MSTO1 fibroblasts as compared with controls. In addition, the abundance of the main fusion (MFN1, MFN2, and OPA1) and fission (DRP1) proteins was unaltered in MSTO1 fibroblasts (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>F).</p>
      </sec>
      <sec id="emmm201607058-sec-0013">
        <title>MSTO1 overexpression restores mitochondrial fusion dynamics in MSTO1 patient fibroblasts</title>
        <p>To test whether normal mitochondrial fusion phenotype can be restored by MSTO1 overexpression in MSTO1 patient fibroblasts, a bicistronic expression vector for MSTO1 and mtDsRed was created (mtDsRed1âT2AâMSTO1). Upon transfection of the P2 fibroblasts with this vector, the abundance of MSTO1 protein was greatly increased as compared with pcDNAâtransfected cells (186%, FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>A). Only a hardly noticeable band appeared at the expected molecular weight of the mtDsRed1âT2AâMSTO1 complex, indicating that it was effectively processed to give rise to separated MSTO1 and mtDsRed proteins (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <title>
<styled-content style="fixed-case">MSTO</styled-content>1 overexpression in <styled-content style="fixed-case">MSTO</styled-content>1 patient fibroblasts</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0005"><list-item><p>Representative Western blot of MSTO1 protein expression after mtDsRed1âT2AâMSTO1 vector delivery (representative of three experiments).</p></list-item><list-item><p>Image time series showing representative pcDNAâ and mtDsRed1âT2AâMSTO1âtransfected fibroblast cell before and after 2P photoactivation of mtPAâGFP (white squares) as in FigÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>A.</p></list-item><list-item><p>The time course of the ratio of <italic>F</italic>
<sub>mtPAâGFP</sub> to <italic>F</italic>
<sub>mtDsRed</sub> for the region of photoactivation (RPA) (left); the decay of the fluorescence ratio in the RPA at 500Â s (right). Stars indicate the significant differences (Student's <italic>t</italic>âtest: *<italic>PÂ </italic>=Â 0.00412, ANOVA: <italic>P</italic>Â =Â 0.00859) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Rates of fusion events in primary fibroblasts. Stars indicate the significant differences (Student's <italic>t</italic>âtest: *<italic>P</italic>Â =Â 1.71Â ÃÂ 10<sup>â4</sup>, ANOVA: <italic>P</italic>Â =Â 0.00343) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Average duration of fusion events which were followed by fission during the 8âmin recording time (meanÂ Â±Â SEM).</p></list-item><list-item><p>Distribution of transient and complete type fusion events.</p></list-item><list-item><p>Orientation characteristics of fusion events in different fibroblasts (meanÂ Â±Â SEM).</p></list-item></list>Data information: (CâG) Number of fusions: mtDsRed1âT2AâMSTO1: <italic>N</italic>Â =Â 188; pcDNAÂ +Â DsRed <italic>N</italic>Â =Â 127; number of imaged cells: mtDsRed1âT2AâMSTO1: 35; pcDNAÂ +Â DsRed <italic>N</italic>Â =Â 36; from â¥Â 2 experiments per each cells.<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="EMMM-9-967-g008"/>
        </fig>
        <p>To evaluate fusion dynamics, the fibroblasts were then coâtransfected with mtPAâGFP and either mtDsRed1âT2AâMSTO1 or mtDsRed and pcDNA. In the microscopy studies, the MSTO1 overexpressing cells were identified based on the mtDsRed fluorescence (images in FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>B). The spreading of mtPAâGFP fluorescence from the areas of photoactivation was accelerated in the MSTO1 overexpressing cells (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>B). The decrease in the fluorescence ratio at the RPA was significantly greater after MSTO1 transfection and was similar to the average value of the three controls (MSTO1âtransfected P2 cells: 0.37Â Â±Â 0.02; only mtDsRedâtransfected MSTO P2 cells: 0.2Â Â±Â 0.01; average of controls: 0.35Â Â±Â 0.02Â s) (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>C). The average halfâtime of the GFPâonly pixel loss was decreased significantly in the MSTO1 overexpressed cells (pcDNAâtransfected cells: 1,714Â Â±Â 300Â s, MSTO1âtransfected cells: 954Â Â±Â 137Â s, <italic>n</italic>
<sub>pcDNA</sub>Â =Â 34; <italic>n</italic>
<sub>MSTO1</sub>Â =Â 36; <italic>P</italic>Â =Â 0.00343). The MSTO1 gene delivery normalized the fusion numbers as well (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>D). After MSTO1 transfection, the average fusion number was 5.2Â Â±Â 0.4/run (0.65Â Â±Â 0.0/min), while in the mtDsRedâtransfected cells 3.52Â Â±Â 0.3/run (0.44Â Â±Â 0.02/min) fusion events were counted (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>D). As a reference, the average fusion numbers of control fibroblasts were 6.4Â Â±Â 0.1/run, 0.8Â Â±Â 0.0/min (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>D). However, MSTO1 overexpression did not alter the reversibility (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>E), duration (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>F), and orientation (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>G) of the fusion events.</p>
      </sec>
      <sec id="emmm201607058-sec-0014">
        <title>MSTO1 silencing inhibits mitochondrial fusion in HeLa cells</title>
        <p>Next, in order to avoid the complexities and high variability of the cells derived from different individuals, the possible contribution of MSTO1 to fusion dynamics was assessed in HeLa cells. Gene silencing was performed with either MSTO1âtargeting or scrambled siRNA. Immunoblotting confirmed the MSTO1 depletion (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>A). Following 72âh silencing, the protein amount of MSTO1 was 49Â Â±Â 3% compared to the scrambled siRNA control. In the MSTO1âsilenced cells, the expression of MFN1, MFN2, OPA1, and DRP1 was not significantly changed (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <title>
<styled-content style="fixed-case">MSTO</styled-content>1 silencing in HeLa cells</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0006"><list-item><p>Protein expression of MSTO1 and the main fusion and fission proteins after MSTO1 silencing. Top: representative blots; bottom: normalized protein abundance of the percentage of the average protein expression levels of the scramble siRNAâtreated cells (<italic>N</italic>Â =Â 3) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Image time series showing a representative MSTO1â and scramble siRNAâsilenced HeLa cell before and after 2P photoactivation of mtPAâGFP (white squares) as in FigÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>A.</p></list-item><list-item><p>The time course of the ratio of <italic>F</italic>
<sub>mtPAâGFP</sub> to <italic>F</italic>
<sub>mtDsRed</sub> for the region of photoactivation (RPA) (left); the decay of the fluorescence ratio in the RPA at 500Â s (right). Stars indicate the significant differences (Student's <italic>t</italic>âtest: *<italic>P</italic>Â =Â 5.4Â ÃÂ 10<sup>â4</sup>, oneâway ANOVA: <italic>P</italic>Â =Â 0.03678) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Rates of fusion events in silenced HeLa cells. Stars indicate the significant differences (Student's <italic>t</italic>âtest: *<italic>P</italic>Â =Â 7.15Â ÃÂ 10<sup>â19</sup>, oneâway ANOVA: <italic>P</italic>Â &lt;Â 0.00001) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Average duration of fusion events which were followed by fission during the 8âmin recording time. Stars indicate the significant differences (Student's <italic>t</italic>âtest: *<italic>P</italic>Â =Â 3.67Â ÃÂ 10<sup>â4</sup>, oneâway ANOVA: <italic>P</italic>Â =Â 0.00052) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Distribution of transient and complete type fusion events.</p></list-item><list-item><p>Orientation characteristics of fusion events in silenced and control HeLa cells (meanÂ Â±Â SEM).</p></list-item></list>Data information: (CâG) Number of fusions: MSTO1 siRNA <italic>N</italic>Â =Â 386; Scr. siRNA <italic>N</italic>Â =Â 563; number of imaged cells: MSTO1 siRNA <italic>N</italic>Â =Â 54; Scr. siRNA <italic>N</italic>Â =Â 50; from three experiments. <named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-17" xlink:href="EMMM-9-967-g009"/>
        </fig>
        <p>Mitochondrial fusion dynamics was evaluated upon coâtransfection of the siRNAâtreated cells with mtPAâGFP and mtDsRed. The siMSTO1 cells showed increased mitochondrial fragmentation (FigÂ <xref rid="emmm201607058-fig-0002ev" ref-type="fig">EV2</xref>D and E) and relatively slow spreading of mtPAâGFP from the photoactivation areas (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>B and C). Applying the fusion quantification algorithm, the average halfâtime of the GFPâonly pixel loss, which inversely correlates with mitochondrial fusion activities, was increased significantly in the MSTO1âsilenced cells (MSTO1âsilenced cells: 505Â Â±Â 101Â s, scramble siRNAâsilenced cells: 247Â Â±Â 20Â s, <italic>n</italic>
<sub>Scr</sub>Â =Â 45; <italic>n</italic>
<sub>MSTO1</sub>Â =Â 58; <italic>P</italic>Â &lt;Â 0.00001). Consistent with this, the manually counted fusion number also decreased in the siMSTO1 condition (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>D). After MSTO1 siRNA transfection, the average fusion number was 10.9Â Â±Â 0.1/run, while in the scramble siRNAâtransfected cells 20.1Â Â±Â 0.5/run fusion events were counted (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>D). The average duration of the fusion events slightly increased upon MSTO1 targeting (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>E), whereas the distribution of the different fusion types (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>F) and the orientation of the fusion events (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>G) were not changed.</p>
      </sec>
      <sec id="emmm201607058-sec-0015">
        <title>Mitochondrial motility is maintained in patient fibroblasts</title>
        <p>We have previously shown that mitochondrial fusion can be controlled indirectly through changes in mitochondrial motility (Liu <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0013" ref-type="ref">2009</xref>; Twig <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0027" ref-type="ref">2010</xref>). Therefore, mitochondrial motility was quantified in the MSTO1 patient fibroblasts as well as in the controls in sideâbyâside comparisons (FigÂ <xref rid="emmm201607058-fig-0003ev" ref-type="fig">EV3</xref>). The results show that P2 had similar mitochondrial movement activity to Ctrl1 and more than Ctrl2 (<italic>P</italic>Â =Â 0.97 and <italic>P</italic>Â =Â 0.0063, respectively, KruskalâWallis oneâway ANOVA, Dunn's multiple comparison test), and P1 was similar to Ctrl3 in terms of mitochondrial motility (<italic>P</italic>Â =Â 0.10, MannâWhitney rank sum test). Thus, the decrease in mitochondrial fusion is not secondary to a decrease in mitochondrial motility in the MSTO1âdeficient patient cells.</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="emmm201607058-fig-0003ev" orientation="portrait" position="float">
          <label>Figure EV3</label>
          <caption>
            <title>Motility analysis from fusion records</title>
            <p>To estimate mitochondrial motility in MSTO1 patient and control fibroblasts from records used for fusion analysis, the green and red channels were combined by addition. From the resulting image (summed image), a difference image series was generated by subtracting successive images. Both the difference image series and the summedÂ images were thresholded by a constant value (32 in an 8âbit image) and the number of pixels above the threshold in the period after the photoactivation was determined. The final measure is given as the median number of pixels above the threshold from the difference image series normalized by the median number of pixels above the threshold from the summed image series. Horizontal line shows the median value; box, the 25<sup>th</sup> and 75<sup>th</sup> percentiles; error bars, 10<sup>th</sup> and 90<sup>th</sup> percentiles; circles are individual outlying cells. The overall fluorescence intensity of the cells was also measured (mean intensity of pixels above threshold) in the summed image, and no significant differences in intensity between groups were found (<italic>P</italic>Â =Â 0.395, oneâway ANOVA). Data are from six experiments: three comparing P1 and Ctrl3, two comparing P2 and Ctrl2, and one with P2 and Ctrl1; the number of cells in each group is indicated.</p>
          </caption>
          <graphic id="nlm-graphic-19" xlink:href="EMMM-9-967-g007"/>
        </fig>
      </sec>
      <sec id="emmm201607058-sec-0016">
        <title>Mitochondrial membrane potential, Ca<sup>2+</sup> uptake, and respiration after MSTO1 silencing</title>
        <p>To determine whether the effect of MSTO1 silencing on mitochondrial fusion might be secondary to an effect on mitochondrial bioenergetics, the mitochondrial membrane potential (ÎÎ¨<sub>m</sub>) and Ca<sup>2+</sup> uptake were determined. The resting ÎÎ¨<sub>m</sub> and the ÎÎ¨<sub>m</sub> loss evoked by Ca<sup>2+</sup> additions were similar in both MSTO1â and scramble siRNAâsilenced cells (FigÂ <xref rid="emmm201607058-fig-0006" ref-type="fig">6</xref>A). The resting âcytoplasmicâ [Ca<sup>2+</sup>] and the transients caused by CaCl<sub>2</sub> boluses were also similar in the MSTOâ and scrambled siRNAâtreated cells (FigÂ <xref rid="emmm201607058-fig-0006" ref-type="fig">6</xref>B).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <title>Mitochondrial membrane potential and mitochondrial Ca<sup>2+</sup> uptake after <styled-content style="fixed-case">MSTO</styled-content>1 silencing</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0007"><list-item><p>ÎÎ¨<sub>m</sub> measured using TMRE in suspensions of permeabilized HeLa cells. Increase in fluorescence after each CaCl<sub>2</sub> pulse indicates depolarization. Left inset shows resting ÎÎ¨<sub>m</sub> as initial TMRE fluorescence normalized to the fluorescence attained after complete depolarization by uncoupler (5Â Î¼M FCCP). Left graphs shows the ÎÎ¨<sub>m</sub> loss evoked by Ca<sup>2+</sup> pulses (4 and 3 pairs of scrambled and MSTO siRNAâsilenced cells per measurement from two independent experiments). Arrows indicate the CaCl<sub>2</sub> additions (20Â Î¼M each) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Clearance of Ca<sup>2+</sup> by mitochondria. The cells were challenged by repetitive CaCl<sub>2</sub> pulses (20Â Î¼M each). Ca<sup>2+</sup> uptake is shown in the representative traces by the decay of the [Ca<sup>2+</sup>] increases evoked by each CaCl<sub>2</sub> addition (arrows). Left inset shows the mean resting âcytoplasmicâ Ca<sup>2+</sup> concentrations, the left graph shows mitochondrial Ca<sup>2+</sup> uptake after each Ca<sup>2+</sup> pulse (4 and 3 pairs of scrambled and MSTO siRNAâsilenced cells per measurement from two independent experiments) (meanÂ Â±Â SEM).</p></list-item><list-item><p>JO<sub>2</sub> was measured using the Seahorse XF24 analyzer and calculated by subtracting the O<sub>2</sub> consumption rates measured prior to injecting the complex III inhibitor antimycin A (1Â Î¼M) from the rate measured after antimycin addition. Basal JO<sub>2</sub> refers to the JO<sub>2</sub> in cells exposed only to DMEMÂ +Â substrates. Maximal JO<sub>2</sub> refers to the JO<sub>2</sub> after injecting the chemical uncoupler FCCP (250Â nM). <italic>P</italic>âvalue was calculated using Student's <italic>t</italic>âtest (<italic>P</italic>Â =Â 0.01). <italic>n</italic>Â =Â 5 different passages per siRNA treatment (meanÂ Â±Â SEM).</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-21" xlink:href="EMMM-9-967-g010"/>
        </fig>
        <p>Respiration function measurements showed that MSTO silencing was without major effect on basal (FigÂ <xref rid="emmm201607058-fig-0006" ref-type="fig">6</xref>C) or leakâdependent JO<sub>2</sub>, but led to a slight but significant lowering of the maximal electron transport chain activity (FigÂ <xref rid="emmm201607058-fig-0006" ref-type="fig">6</xref>C) as determined by injecting the chemical uncoupler FCCP.</p>
        <p>Thus, ÎÎ¨<sub>m</sub> generation, mitochondrial Ca<sup>2+</sup> accumulation and basal respiration do not seem to be affected by shortâterm MSTO1 depletion, indicating that suppression of mitochondrial fusion is not secondary to a change in mitochondrial bioenergetics.</p>
      </sec>
      <sec id="emmm201607058-sec-0017">
        <title>MSTO1 protein is mainly localized in the cytoplasmic area and shows partial colocalization with the mitochondria</title>
        <p>In HeLa cells, overexpression of either MSTO1âMyc or mtDsRed1âT2AâMSTO1 caused an increase in MSTO1 protein amount (465 and 542%, respectively, compared to that in the pcDNAâtransfected cells, FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>A). Again, the 80Â kDa band representing the uncleaved mtDsRed1âT2AâMSTO1 complex was faint (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <title>Subcellular localization of <styled-content style="fixed-case">MSTO</styled-content>1 protein</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0008"><list-item><p>Representative Western blot of MSTO1 protein expression after both MSTO1âMyc and mtDsRed1âT2AâMSTO1 gene delivery compared to the pcDNAâtransfected cell lysate.</p></list-item><list-item><p>Subcellular distribution of MSTO1, immunofluorescence visualization was performed with antiâMSTO1 antibody in HeLa cells, which were transfected with mtDsRed1âT2AâMSTO1 vector 24Â h before fixation.</p></list-item><list-item><p>Localization of MSTO1 protein after 24âh cotransfection with an OMMâtargeted GFP (OMP25âGFP) and MSTOâcMyc vectors. The intact (upper part) and permeabilized (lower part) cells were immunostained with antiâMSTO1 or antiâcMyc antibodies.</p></list-item><list-item><p>Percentage of MSTO1 colocalization with the mitochondria in intact cells (imaged cells <italic>N</italic>Â =Â 30) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Percentage of MSTO1 colocalization with the mitochondria in permeabilized cells (imaged cells <italic>N</italic>Â =Â 30) (meanÂ Â±Â SEM).</p></list-item><list-item><p>Comparative Western blotting of the MSTO1 expression in total cell lysate and isolated mitochondria fraction in HeLa cells.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-23" xlink:href="EMMM-9-967-g011"/>
        </fig>
        <p>To test the subcellular distribution of MSTO1, immunostaining was performed. HeLa cells transfected with mtDsRed1âT2AâMSTO1 vector were stained with antiâMSTO1 antibody 24Â h after transfection. MSTO1 did not show colocalization with the mitochondria; rather, intense MSTO1 staining was present in the whole cytoplasmic area (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>B). To further investigate the localization of MSTO1 protein, HeLa cells were coâtransfected with OMMâtargeted GFP (OMP25âGFP) and MSTOâcMyc vectors. 24Â h after transfection, the coverslips were divided into two groups. One group was permeabilized with digitoninÂ (30Â Î¼g/ml) before fixation, while the other group was just fixed. Both the intact and permeabilized cells were stained with antiâMSTO1 or antiâcMyc antibodies. In the intact cells, the MSTO1/Myc signal and mitochondrial targeted OMP25âGFP colocalization was approx. 30% (MSTO1 staining: 29Â Â±Â 2.7%; câMyc staining: 33.1Â Â±Â 2.1%) (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>C and D). In the permeabilized cells, most of the MSTO1/câMyc immunostaining disappeared, and for the remaining signal, the colocalization was around 50% (MSTO1 staining: 56Â Â±Â 1.2%; câMyc staining: 48.2Â Â±Â 3.1%) (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>C lower images; and FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>E).</p>
        <p>To complement these results, endogenous MSTO1 protein abundance was assessed by immunoblotting in both total cell lysate and mitochondria isolated from HeLa cells. When normalized to the amount of the mitochondrial loading control, prohibitin, the MSTO1 protein amount was relatively low, only 35% in the mitochondrial fraction (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>F).</p>
      </sec>
      <sec id="emmm201607058-sec-0018">
        <title>MSTO1 protein is soluble</title>
        <p>Permeabilization of the plasma membrane resulted in almost complete loss of the immunofluorescence, whereas the mitochondrial markers stayed (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>C), indicating that MSTO1 cannot be an integral or firmly associated mitochondrial protein. Then, it became important to determine how this protein could interact with the mitochondrial fusion proteins, which are transmembrane components of the OMM or IMM. Therefore, we compared the release upon plasma membrane permeabilization of MSTO1 to other cellular proteins (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>A). After plasma membrane permeabilization, in both the MSTO1âtransfected and nonâtransfected HeLa cells, the MSTO1 protein is promptly and almost completely released into the cytoplasmic fraction. In MSTO1 transfected cells after 140 s more than 60% of MSTO1 protein was released into the cytoplasmicfraction, while in the nonâtransfected cells MSTO1 release was even higher, approximately 88% (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>B). For comparison, we tested the release of proteins with known localization. Hexokinase II, known to be loosely bound to the OMM (Chiara <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0005" ref-type="ref">2008</xref>), showed less and slower release than MSTO1 in both conditions (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>B). The Î±âtubulin, a soluble cytosolic protein, showed a very similar release pattern to MSTO1 (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>B). After saponin treatment, in the control and MSTO1 primary fibroblast cells, similar protein releases were found.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201607058-fig-0008" orientation="portrait" position="float">
          <label>Figure 8</label>
          <caption>
            <title>
<styled-content style="fixed-case">MSTO</styled-content>1 protein release after plasma membrane permeabilization</title>
            <p>
<list list-type="alpha-upper" id="emmm201607058-list-0009"><list-item><p>Representative Western blots of MSTO1, hexokinase II, Î±âtubulin, and cytochrome c in membrane and supernatant fractions of MSTO1âcMycâtransfected and nonâtransfected cells.</p></list-item><list-item><p>Protein release of MSTO1, hexokinase II, Î±âtubulin after plasma membrane permeabilization (values are normalized to the intact cells). <italic>N</italic>Â =Â 3 (meanÂ Â±Â SEM).</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-25" xlink:href="EMMM-9-967-g012"/>
        </fig>
        <p>Mitochondrial intermembrane space proteins represented by cytochrome c were not released following digitonin or saponin treatments, since the OMM is more resistant to these detergents than the plasma membrane. However, cytochrome c redistributed to the cytoplasmic fraction upon tBid (proâapoptotic Bcl2 protein) addition (Willis <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0031" ref-type="ref">2007</xref>). Lastly, permeabilized cells were exposed to limited proteolysis with trypsin (100 Î¼g/ml), followed by addition of soybean trypsin inhibitor (250Â Î¼g/ml) (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>). After trypsin treatment, the MSTO, like hexokinase or Î±âtubulin, disappeared from both the cytoplasmic and membrane fractions, which further indicated that MSTO1 is localized out of the mitochondria and it can be loosely bound to the OMM.</p>
      </sec>
    </sec>
    <sec id="emmm201607058-sec-0019">
      <title>Discussion</title>
      <p>In this report, we described the first identified human diseaseâassociated variation of <italic>MSTO1</italic> gene in a patient with multisystemic clinical phenotype. Furthermore, we demonstrated that MSTO1 has a role in mitochondrial morphogenesis and quality control by supporting mitochondrial fusion. MSTO1 likely interacts with the mitochondrial fusion machinery as a soluble factor at the cytoplasmâOMM interface.</p>
      <p>Sequencing of DNA isolated from the blood (whole exome and Sanger sequencing) assumed that Val8Met mutation in the <italic>MSTO1</italic> gene is responsible for the clinical symptoms in the present family. The cDNA sequencing confirmed the heterozygous V8M, while in the genomic DNA no exon loss or multiplication was found in this gene. Thus, the Hungarian patients seem to have one impaired and oneÂ normal MSTO1 allele, which result in a partial decrease in MSTO1 mRNA and protein levels. Based on combination of several criteria, no other knownÂ pathogenic mutation is segregated in this family, but we cannot exclude that partial loss of MSTO1 comes together with some other factors toÂ cause the patients clinical picture. Notably, several mitochondriaâassociated protein disturbances (e.g., <italic>POLG1, RRM2B, OPA1, MFN2</italic>) can be inherited in both autosomal dominant and recessive manner. Based on previous observation, the autosomal recessive forms usually associated with severe, earlyâonset phenotypes, while in the autosomal dominant forms linked to milder, adultâonset manifestations (Tyynismaa <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0028" ref-type="ref">2009</xref>). Lossâofâfunction mutations are usually associated with a lower amount of the expressed proteins, but depending on its monoâ or biallelic features, the remaining protein level could be different. For example in the case of OPA1, the autosomal dominant mutations are associated with reduced OPA1 expression (Bonifert <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0001" ref-type="ref">2014</xref>), while for the recessive form almost absent protein expression was found (Spiegel <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0025" ref-type="ref">2016</xref>).</p>
      <p>Human Misato (MSTO1) was described as an evolutionarily conserved OMM protein, and it has been implicated in the control of mitochondrial morphology (Miklos <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0016" ref-type="ref">1997</xref>; Gurvitz <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0008" ref-type="ref">2002</xref>; Kimura &amp; Okano, <xref rid="emmm201607058-bib-0010" ref-type="ref">2007</xref>). Our experiments extended this observation by demonstrating that a decrease in MSTO1 protein in patient fibroblasts as well as in HeLa cells upon MSTO1 acute silencing was associated with a decrease in mitochondrial fusion activity specifically (FigsÂ <xref rid="emmm201607058-fig-0002" ref-type="fig">2</xref>, <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>, <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>, <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>). The causeâeffect relationship between MSTO1 decrease and fusion inhibition was validated by genetic rescue studies in the patient fibroblasts (FigÂ <xref rid="emmm201607058-fig-0004" ref-type="fig">4</xref>). Since the decrease in mitochondrial fusion was observed upon 72âh silencing, it unlikely results from a complex adaptation process. Furthermore, we have shown that at the same time point, no impairment in ÎÎ¨<sub>m</sub> or Ca<sup>2+</sup> handling or basal respiration was noticeable (FigÂ <xref rid="emmm201607058-fig-0006" ref-type="fig">6</xref>). Thus, fusion inhibition is not secondary to an impairment of bioenergetics when MSTO1 is decreased.</p>
      <p>In both fusion and fission, the key factors are the large GTPase enzymes belonging to the large dynamin superfamily; fusion is mainly regulated by MFN1, MFN2, and OPA1 (Meeusen <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0015" ref-type="ref">2006</xref>; Song <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0024" ref-type="ref">2009</xref>), while fission requires mainly DRP1 (Otera <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0021" ref-type="ref">2010</xref>; Loson <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0014" ref-type="ref">2013</xref>). However, the protein expression of these proteins was unaltered in MSTO1 fibroblasts (FigÂ <xref rid="emmm201607058-fig-0003" ref-type="fig">3</xref>F) as well as in HeLa cells after MSTO1 silencing (FigÂ <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>A).</p>
      <p>MSTO1 protein was originally described as an OMM protein; it was coâlocalized with cytochrome c and MitoTracker Orange in HeLa cells (Kimura &amp; Okano, <xref rid="emmm201607058-bib-0010" ref-type="ref">2007</xref>), and thus, it could be an OMM fusion mediating factor. However, in our experiments, both overexpressed (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>) and endogenous (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>) MSTO1 showed cytoplasmic localization. Since the majority of endogenous MSTO1 was promptly released upon plasma membrane permeabilization with a small fraction remaining associated with membranes (FigÂ <xref rid="emmm201607058-fig-0008" ref-type="fig">8</xref>), including the mitochondria (FigÂ <xref rid="emmm201607058-fig-0007" ref-type="fig">7</xref>), MSTO1 likely is a soluble cytoplasmic protein that might interact with OMM components. Thus, MSTO1 might serve as a cytoplasmic regulator of the OMM fusion machinery. Interestingly, partial depletion of MSTO1 is sufficient to impair fusion (FigsÂ <xref rid="emmm201607058-fig-0001" ref-type="fig">1</xref> and <xref rid="emmm201607058-fig-0005" ref-type="fig">5</xref>), indicating that MSTO1 might be quantitatively required for normal mitochondrial fusion activity. However, because of the lack of direct evidence for an interaction of MSTO1 with a fusion protein, we cannot completely exclude the possibility that the decrease in MSTO1 induces a generic cellular stress response. The main argument against this mechanism is that many aspects of cell and mitochondrial function, including motility and bioenergetics remained unaltered in the MSTO1âdeficient cells. In any case, further mechanistic studies will be needed to determine the exact mechanism of the fusion supporting role of MSTO1.</p>
      <p>Mitochondrial fusion is central for the maintenance of mtDNA and function (Ono <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0020" ref-type="ref">2001</xref>; Chan, <xref rid="emmm201607058-bib-0002" ref-type="ref">2006</xref>; Chen <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0004" ref-type="ref">2010</xref>). It is sensible that shortâterm depletion of MSTO1 did not impair bioenergetics but on the long run in the patients, MSTO1 depletion is expected to cause some impairment in mitochondrial function. Notably, recent results indicate that impaired trafficking of functional mitochondria can also cause neuronal and other tissue's dysfunction (Nguyen <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0019" ref-type="ref">2014</xref>) and mitochondrial movements are affected by the fusion dynamics (Liu <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0013" ref-type="ref">2009</xref>). However, MSTO1 also has an involvement in cell division that might be also relevant for some congenital malformations of the proband. <italic>DML1</italic> and <italic>Misato</italic> might be coâopted into a role in mtDNA inheritance in yeast, and into a cell divisionârelated mechanism in flies. The mutations of <italic>DML1</italic> or <italic>Misato</italic> could inhibit kinetochoreâdriven microtubules growth, associated with a strong mitotic defect; and it has an additional function in the partitioning of mitochondrial organelle itself, or in segregation of chromosomes (Miklos <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0016" ref-type="ref">1997</xref>; Gurvitz <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0008" ref-type="ref">2002</xref>; MottierâPavie <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0018" ref-type="ref">2011</xref>).</p>
      <p>In conclusion, our findings indicate that MSTO1 has a role in mitochondrial morphogenesis and maintenance by specifically supporting mitochondrial fusion. In contrast to previous findings, MSTO1 likely interacts with the mitochondrial fusion machinery as a soluble factor at the cytoplasmâOMM interface. Since a lossâofâfunction mutation in MSTO1 is associated with impaired mitochondrial dynamics and several symptoms characteristic to mitochondrial disease patients, MSTO1 might be a factor in diseases that have a mitochondrial component.</p>
    </sec>
    <sec id="emmm201607058-sec-0020">
      <title>Materials and Methods</title>
      <sec id="emmm201607058-sec-0021">
        <title>Patient selection and clinical investigations</title>
        <p>The patients and controls were collected from the NEPSY Biobank of the Institute of Genomic Medicine and Rare Disorders, Semmelweis University (Molnar &amp; Bencsik, <xref rid="emmm201607058-bib-0017" ref-type="ref">2006</xref>). Written informed consent was obtained from each individual before sample collection and molecular genetic testing. The study was approved by the National Ethical Committee (37/2014 TUKEB). Molecular genetic analysis was performed for diagnostic purposes in all investigated patients.</p>
        <p>Detailed neurological, cardiology, psychiatric examinations, and laboratory investigations were performed. Skeletal muscle biopsy was obtained for light and electron microscopic examination using standard routine staining. Electroneurography and electromyography were performed by standard techniques (Dantech Keypoint, Denmark).</p>
      </sec>
      <sec id="emmm201607058-sec-0022">
        <title>Molecular genetic studies</title>
        <p>DNA was extracted from blood and skeletal muscle using QIAamp DNA blood and tissue kits, according to the instructions of manufacturer (QIAGEN, Hilden, Germany).</p>
        <p>The total coding region of mtDNA was screened by Sanger sequencing using ABI Prism 3500 DNA Sequencer (Applied Biosystems, Foster City, USA); the obtained sequences were compared with the mitomap databases using NCBI's Blast<sup>Â®</sup> application, while mtDNA deletion was investigated with long PCRs using Phusion HighâFidelity DNA Polymerase (Finnzyme, Vanta, Finland).</p>
        <p>Exome Capture was performed in two steps according to the manufacturer's protocol. Genomic DNA library preparation was performed by usingÂ TruSeq<sup>Â®</sup> DNA Sample Prep Kit v2âSet A (Illumina), followed by NimbleGen SeqCap EZ Human Exome Library v3.0 Kit exomeÂ enrichment (Roche). First preâcapture genomic library was prepared using 1Â Î¼g of highly purified genomic DNA. Crude preâcaptured genomic library was analyzed by Agilent 2100 Bioanalyzer 1000 DNA chip to assess library quality. Next, during exome enrichment step, individual preâcaptured libraries were hybridized to biotinylated NimbleGen SeqCap EZ Human Exome Library for 68â70Â h at 47Â°C. Hybridized libraries were captured by magnetic Dynabeads MyOne Streptavidin C1 (Thermo Fisher Scientific). Streptavidin beads were washed, and the captured DNA was eluted. Eluted DNA was PCR amplified by 18 cycles. Crude targetâcaptured libraries were gel purified on 2% EâGel (Life Technologies) and cleaned up with QIAquick Gel Extraction Kit (QIAgen, Hilden, Germany). Targetâcaptured, gelâpurified libraries were analyzed by Agilent 2100 Bioanalyzer 1000 DNA chip to assess libraries quality. The final library concentration was determined by manual integration of molecular profile by Agilent 2100 Bioanalyzer 1000 DNA chip. Illumina adaptorâspecific qPCR was also performed for each library to measure the library template concentration containing adaptor sequences on both ends which will subsequently form clusters on the Illumina flow cell. AllÂ library pools were sequenced on the HiScanSQ Illumina sequencing platform, using 2Â ÃÂ 95âbp pairâend sequencing protocol, with an extra 9âbp index sequencing run. Final exomeâcaptured<sup>Â </sup>sequencing libraries were diluted to 10Â nM. Reads were filtered according to the Q30 standard. 95âbp pairedâreads were aligned to the human reference genome (hg19). The alignment was performed using BurrowsâWheeler aligner (BWA) software. For variation calling, Samtools software was used (Li <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0011" ref-type="ref">2009</xref>; Li, <xref rid="emmm201607058-bib-0012" ref-type="ref">2011</xref>). After identification of variants, we focused only on nonâsynonymous variants, splice acceptor and donor site mutations, and short, frame shift coding insertions or deletions (indel) using Genomes Management Application (GEM.app) software (Department of Human Genetics, University of Miami Health System, and Miami, FL, USA).</p>
        <p>The WES filtering procedure was the following: GATK (QUAL)Â &gt;Â 50, GQÂ &gt;Â 40, RDÂ &gt;Â 4 quality scores; autosomal dominant inheritance; only the missense, nonsense, indels, and spliceâsite rare variants with MAFÂ &lt;Â 0.01 were selected. All SNVs higher than three occurrences in GEMapp were excluded.</p>
        <p>For crosschecking, the mitochondrial genetic alterations were investigated by targeted screening for both autosomal dominant and recessive inheritance performed in genes, which is responsible for mitochondrial function. The rare variants were filtered out based on mitochondrial gene function and disease association used a gene list, which was created by UNIPROT, NextProt, MitoMiner, and NCBI databases.</p>
        <p>As largeâscale genomic data are not available from the Hungarian population, a mutation with low minor allele frequency may be population specific. Finally, we prioritized mutations based on consequence. Exonic frameshift and stop mutations were considered as damaging. Missense mutations were prioritized, which was based on the protein prediction score annotations given by ANNOVAR (Wang <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0029" ref-type="ref">2010</xref>). Further narrowing was based on protein prediction scores (Polyphen2 scoreÂ &gt;Â 0.5, Mutation taster: disease causing, SIFTÂ &lt;Â 0.1, PHASTCONSÂ &gt;Â 0.5; GERPÂ &gt;Â 3). Using ACMG guideline (Richards <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0023" ref-type="ref">2015</xref>), the pathogenic and likely pathogenic variants were confirmed by Sanger sequencing.Â After identification of candidate alterations, the segregation analysis was performed in all affected family members.</p>
        <p>For the validation of the exome capture result <italic>COL5A1</italic> Exon 3, total coding region of <italic>MSTO1</italic> from genomic and cDNA, <italic>RELN</italic> Exon 62, <italic>RYR2</italic> Exon 16, were analyzed with bidirectional Sanger sequencing (the primers listed in <xref rid="emmm201607058-sup-0003" ref-type="supplementary-material">TableÂ EV2</xref>). The obtainedÂ sequences were compared with the human reference genome (ENST00000371817, NM_000093.4; ENST00000245564, NM_018116.3; ENST00000343529, NM_173054.2; ENST00000366574, NM_001035.2) using NCBI's Blast<sup>Â®</sup> application.</p>
        <p>The analysis of copy number variation of all exons of <italic>MSTO1</italic> gene was performed by quantitative realâtime RTâPCR with SYBG methodology in the realâtime PCR StepOnePlus system according the manufacturer's instructions (Life Technology). For quantification, the ddCt method was used.</p>
      </sec>
      <sec id="emmm201607058-sec-0023">
        <title>RNA isolation and RTâPCR</title>
        <p>Total cellular RNA was isolated using by RNeasy Plus Mini Kit, according to the instructions of manufacturer (QIAgen, Hilden, Germany). cDNA was synthesized by high Sensitive cDNA reverse transcriptase kit (Life Technology) according to the manufacturer's instructions. For measuring mRNA level, RTâPCR products were analyzed by quantitative realâtime RTâPCR with TaqMan Gene Expression Assays of MSTO1 genes (Hs01094406_g1), and GAPDH (Hs02758991_g1) as endogenous control (Life Technology). All PCRs were performed in the realâtime PCR StepOnePlus system. For quantification of gene expression level, the ddCt method was used.</p>
      </sec>
      <sec id="emmm201607058-sec-0024">
        <title>Creation of a MitoâDsRed1âT2AâMSTO1 construct</title>
        <p>Human MSTO1âMyc was purchased from OriGene (clone RC200136). To create the mtDsRed1âT2AâMSTO1 construct, first the sequences of the mtDsRed1 (from the pDsRed1âMito plasmid, Clontech) and the human MSTO1 (from the cDNA clone RC200136, OriGene) were cloned into the pEGFPâN1 plasmid (Clontech) using the NheI and NotI restriction sites. Next, theÂ sequence of the viral T2A peptide was inserted between MitoâDsRed1 and MSTO1 resulting the cleavage of the single mRNAâcoded polypeptide chain intoÂ two pieces during translation (PMID: 22357943). Transfection was performed using Lipofectamine 2000 (Life Technologies) with 0.7â4Â Î¼g of plasmid DNA in serumâfree culture medium for 4Â h.</p>
      </sec>
      <sec id="emmm201607058-sec-0025">
        <title>Cell lines, cultures, and transfections with siRNA and plasmid DNA</title>
        <p>Fibroblasts were generated from a 6âmm skin punch biopsy taken under local anesthetic of healthy control individuals (Ctrl1: 35âyearâold male, Ctrl2: 25âyearâold female, Ctrl3: 57âyearâold male) and patients carrying a c.22 G&gt;A, p.Val8Met mutation in <italic>MSTO1</italic> gene (MSTO P1, MSTO P2). Cells were grown in Dulbecco's modified Eagle's medium (DMEM), with 4.5Â g/l glucose supplemented with 10% fetal bovine serum, 2Â mM glutamate, 100Â units/ml penicillin/streptomycin (all from GIBCO, Life Technology), and 110Â mg/l pyruvate (Sigma). All cells were grown at 37Â°C in a humidified 5% CO<sub>2</sub> incubator. HeLa cells (ATCC) were grown in the aboveâdescribed medium without pyruvate.</p>
        <p>Before silencing, the cells were plated in antibioticâfree medium, and the samples were silenced in serumâfree culture medium with MSTO1âspecific (s30301, Life Technologies) or scrambled siRNAs (Silencer<sup>Â®</sup> Negative Control #1 siRNA, Life Technologies) (100Â nM), using Oligofectamine (Life Technologies) for 72Â h. The efficacy of silencing was verified with Western blotting. For evaluation of mitochondrial morphology and fusion dynamics, the cells were transfected with mtDsRed1 or mtDsRed1âT2AâMSTO1 and mtPAâGFP plasmid DNAs 24Â h before the experiment.</p>
      </sec>
      <sec id="emmm201607058-sec-0026">
        <title>Western blotting</title>
        <p>For Western blotting, 40Â Î¼g of proteins was loaded into each lane of a 12% SDSâPAGE and electrophoretically transferred to nitrocellulose filters. Membranes were blocked with blocking buffer (LIâCOR Biosciences), followed by overnight incubation with primary antibodies (<xref rid="emmm201607058-sup-0004" ref-type="supplementary-material">TableÂ EV3</xref>). Bound antibodies were visualized with IRDye 800 secondary antibodies (LIâCOR Biosciences). Quantification of protein abundance was done by ImageJ software and abundance, and the relevant bands were normalized to loading controls (mtHSP70 or prohibitin).</p>
      </sec>
      <sec id="emmm201607058-sec-0027">
        <title>Mitochondria preparation</title>
        <p>The cells were trypsinized, then trypsin was neutralized with 2% BSA, and the cells were washed with NaâHEPESâEGTA. The pellet was resuspended in a hyposmotic intracellular medium (24Â mM KCl, 0.2Â mM KH<sub>2</sub>PO<sub>4</sub>, 2Â mM NaCl, 4Â mM HEPESâTris, 200Â Î¼M EGTA, 1Â Î¼g/ml of antipain, leupeptin, and pepstatin, 5Â mM MgCl<sub>2</sub>, 100Â Î¼M PMSF) and centrifuged at 1,000Â ÃÂ <italic>g</italic>. The supernatant was homogenized with cell cracker (18Â nm clearance, 15Ã), and the isoosmolarity was restored by addition 125Â mM sucrose, 120Â mM KCl, 1Â mM KH<sub>2</sub>PO<sub>4</sub>, 10Â mM NaCl, 20Â mM HEPESâTris, 200Â Î¼M EGTA, 100Â Î¼M PMSF before centrifugation at 1,000Â ÃÂ <italic>g</italic>. The supernatant was centrifuged at 10,000Â ÃÂ <italic>g</italic>, and the final pellet (mitochondrial fraction) was resuspended in protein lysis buffer (RIPA, 1Â Î¼g/ml antipain, leupeptin, and pepstatin, and 100Â Î¼M PMSF). All steps were performed at 4Â°C.</p>
      </sec>
      <sec id="emmm201607058-sec-0028">
        <title>Immunocytochemistry</title>
        <p>The adherent cells were fixed with 3% paraformaldehyde in fixation buffer at 37Â°C and were immunostained with the antiâMSTO1 (OriGene) or antiâcMyc (Santa Cruz Biotechnology) primary antibodies. The secondary antibodies were labeled with Alexaâ488 and Alexaâ546 (Thermo Fisher Scientific). After staining, the coverslips were postâfixed with 3% paraformaldehyde. In some cases, the cells were permeabilized before the immunostaining. The cells were washed with prewarmed (37<sup>Â°</sup>C) NaâHEPESâEGTA and permeabilized with 30Â Î¼g/ml digitonin in ICM (120Â mM KCl, 10Â mM NaCl, 1Â mM KH<sub>2</sub>PO<sub>4</sub>, 20Â mM TrisâHEPES, pH 7.2, 1Â Î¼g/ml antipain, leupeptin, and pepstatin, 0.4Â mM KOH, and 2Â Î¼M thapsigargin). Image acquisition (512Â ÃÂ 512 pixels) was performed using 488Â nm and 561Â nm laser lines of an LSM780 confocal laserâscanning microscope [63Ã/1.4 NA or 40Ã/1.4 NA, PlanApo (Carl Zeiss)]. Image analysis was done using either Spectralyzer (custom designed) or ImageJ software. The percentage of colocalization was calculated with an ImageJ macro application.</p>
      </sec>
      <sec id="emmm201607058-sec-0029">
        <title>Live cell imaging</title>
        <p>Imaging was performed as previously described (Eisner <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0007" ref-type="ref">2014</xref>; Weaver <italic>etÂ al</italic>, <xref rid="emmm201607058-bib-0030" ref-type="ref">2014</xref>). Briefly, cells were incubated in a 0.25% BSA containing extracellular medium (ECM) consisting of 121Â mM NaCl, 5Â mM NaHCO<sub>3</sub>, 4.7Â mM KCl, 1.2Â mM KH<sub>2</sub>PO<sub>4</sub>, 1.2Â mM MgSO<sub>4</sub>, 2Â mM CaCl<sub>2</sub>, 10Â mM glucose, and 10Â mM NaâHEPES, pH 7.4, at 37Â°C. Recordings of mtPAâGFP and mtDsRed (512Â ÃÂ 512 pixels) were performed using 488 and 561Â nm laser lines at 0.25Â /s data acquisition frequency using the LSM780 microscope. To photoactivate PAâGFP in 2P mode, a pulsed laser system (760Â nm, Chameleon; Coherent, Inc.) was applied. Image analysis was done using either Spectralyzer or Zen2010.</p>
      </sec>
      <sec id="emmm201607058-sec-0030">
        <title>Analysis of mitochondrial matrix continuity</title>
        <p>Mitochondrial matrix continuity was evaluated by two different approaches. Spreading of PAâGFP from the area of photoactivation was evaluated by masking the 5Â ÃÂ 5Â Î¼m areas and quantifying the timeâdependent decay in the fluorescence intensity. The images were thresholded to reach a 0.1% noiseâtoâsignal ratio. Then, the pixels of the photoactivated areas were subtracted and the PAâGFPâpositive pixels were counted. Image analysis was performed in Spectralyzer imaging software or in Zen2010. Only cells with the same number of photoactivated areas and no focus loss were compared.</p>
      </sec>
      <sec id="emmm201607058-sec-0031">
        <title>Analysis of GFPâonly pixel loss</title>
        <p>Automated fusion analysis was accomplished by tracking the area of GFPâonly fluorescence after the simultaneous photoactivation/photobleaching of PAâGFP and DsRed/RFP. Briefly, in ImageJ, a rough region of interest was drawn around the entire cell and the period after photoactivation selected; after âdespeckleâ filtering, a single threshold was set for each image series (PAâGFP and RFP) using the Otsu method. The thresholded RFP series was subtracted from the GFP to yield the GFPâonly areas. The number of greenâonly pixels over time was fit by a single exponential (yÂ =Â aeâbx), and the time constant (b) (or halfâtime ln(2)/b) of the exponential decay was used as the measure of fusion. This measure was verified to correlate with the number of fusions by manual counting in recordings of H9c2 cells (<italic>R</italic>
<sup>2</sup>Â =Â 0.698, <italic>P</italic>Â &lt;Â 0.0001, <italic>n</italic>Â =Â 31).</p>
      </sec>
      <sec id="emmm201607058-sec-0032">
        <title>Fluorometric measurements of mitochondrial membrane potential and Ca<sup>2+</sup> uptake</title>
        <p>The cells (1.6Â mg/ml) were suspended in an ICM supplemented with 2Â mM MgATP, 1Â mM malate, 1Â mM pyruvate, 2Â Î¼M thapsigargin, 1Â Î¼M FuraFF/FA (TEFLabs), and 2Â Î¼M TMRE (Invitrogen). The extramitochondrial Ca<sup>2+</sup> concentration was measured using FuraFF, whereas the deltapsi was assessed with TMRE. Fluorescence was monitored in a multiwavelength excitation/dual wavelength emission fluorimeter (DeltaRAM; Photon Technology International). FuraFF and TMRE fluorescence were recorded simultaneously using 340â380Â nm excitation and 500Â nm emission, and 545Â nm excitation and 580Â nm emission, respectively. Calibration of the FuraFF signal in terms of Î¼M [Ca<sup>2+</sup>] was carried out at the end of each measurement by adding 2Â mM CaCl<sub>2</sub>, followed by 10Â mM EGTA/Tris, pH 8.5. TMRE time courses were normalized to the fluorescence obtained, in the fully depolarized condition upon addition of an uncoupler, 5Â Î¼M FCCP.</p>
        <p>To monitor dynamically the MSTO1 protein distribution, the plasma membrane was permeabilized in suspensions of HeLa cells and human fibroblasts. The HeLa cells were effectively permeabilized with digitonin (30Â Î¼g/ml), while the primary fibroblast resisted to digitonin up to 60Â Î¼g/ml, but undergone plasma membrane permeabilization when exposed to saponin (40Â Î¼g/ml). The amount of digitonin and saponin required was determined by trypan blue uptake (&gt;Â 95% of the cells). The samples were continually stirred in a fluorometer cuvette. At specific time points, the samples were centrifuged at 10,000Â ÃÂ <italic>g</italic> to separate the membrane proteins (pellet) from the cytoplasmic fraction (supernatant). After immunoblotting of the membrane and cytosolic fractions, the protein abundances were normalized to total cellular protein.</p>
      </sec>
      <sec id="emmm201607058-sec-0033">
        <title>Measurement of respiratory function</title>
        <p>HeLa cells were treated with siRNA against MSTO, or scrambled control siRNA, for 72Â h, as already described. The siRNA against MSTO resulted in a ~50% (48%Â Â±Â 9%, meanÂ Â±Â SEM) knockdown of MSTO protein. To perform mitochondrial O<sub>2</sub> consumption rate (JO<sub>2</sub>) experiments using the Seahorse XF24 analyzer, cells were seeded into custom plates at 28,000/well the day before the experiment and cultured overnight. To measure JO<sub>2</sub>, culture media was replaced by assay media (DMEM plus 25Â mM glucose and 4Â mM glutamine as substrates). Cells were then incubated at 37Â°C, zero CO<sub>2</sub> for 45Â min; then, the experiment was started. JO<sub>2</sub> measurements comprised repeated cycles of a 2âmin mix, a 2âmin wait, and a 2âmin measurement. To measure maximal leakâdependent JO<sub>2</sub>, oligomycin (2.5Â Î¼g/ml; ATP synthase inhibitor) was injected. To measure maximal electron transport chain activity under the prevailing substrate conditions, the chemical uncoupler FCCP (250Â nM) was injected. This [FCCP] represents the optimal [FCCP] based on studies in which these cells were exposed to different [FCCP]. To measure nonâmitochondrial O<sub>2</sub> consumption rate, antimycin A (1Â Î¼M; complex III inhibitor) was injected. Mitochondrial O<sub>2</sub> consumption (i.e., JO<sub>2</sub>) was calculated as the rate prior to antimycin minus the rate postâantimycin injection. At the conclusion of each experiment, protein was lysed <italic>inÂ situ</italic> and total protein was measured by the BCA method. JO<sub>2</sub> data were normalized by total protein/well.</p>
      </sec>
      <sec id="emmm201607058-sec-0034">
        <title>Statistics</title>
        <p>The data are shown as the meanÂ Â±Â SEM of cells from at least three independent cultures unless it is specified differently. Significance of differences was calculated by oneâway ANOVA analysis or Student's <italic>t</italic>âtest.</p>
      </sec>
    </sec>
    <sec id="emmm201607058-sec-0036">
      <title>Author contributions</title>
      <p>AG, PB, TG, AH, and LN performed the genetic analysis. MJM supervised all the genetic work, diagnosed the family, and performed the clinical examinations. AG performed all the cell biology studies with the guidance of SN and SKJ. ELS designed and carried out the respiratory function measurements. DW created software for image analysis and PV generated new reagents. GH designed and supervised the cell biology studies. AG, MJM, and GH wrote the manuscript. All the authors critically revised the manuscript for intellectual content.</p>
    </sec>
    <sec id="emmm201607058-sec-0037">
      <title>Conflict of interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec id="emmm201607058-sec-0038">
      <boxed-text position="float" content-type="box" id="emmm201607058-blk-0001" orientation="portrait">
        <caption>
          <title>The paper explained</title>
        </caption>
        <sec id="emmm201607058-sec-0039">
          <title>Problem</title>
          <p>Genetic impairments of mitochondriaâassociated proteins are potential contributors in a range of human disorders, but validation of their variations and determination of their specific functions is difficult.</p>
        </sec>
        <sec id="emmm201607058-sec-0040">
          <title>Results</title>
          <p>This work reveals the first dominant mutation in MSTO1 associated with multisystemic disease in a Hungarian family. Furthermore, the role of MSTO1 in shaping of mitochondria via regulation of mitochondrial fusion is directly demonstrated. At variance with previous work, MSTO1 is shown to be a soluble cytoplasmic protein that can interact with the fusion proteins of the outer mitochondrial membrane.</p>
        </sec>
        <sec id="emmm201607058-sec-0041">
          <title>Impact</title>
          <p>Thanks to a multidisciplinary collaboration among clinicians, geneticists, and cell biologists, MSTO1 is found to be a new diseaseâassociated gene responsible for a rare mitochondrial multisystemic disorder.</p>
        </sec>
      </boxed-text>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data"/>
      <supplementary-material content-type="local-data" id="emmm201607058-sup-0001">
        <caption>
          <p>Expanded View Figures PDF</p>
        </caption>
        <media xlink:href="EMMM-9-967-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-sup-0002">
        <caption>
          <p>TableÂ EV1</p>
        </caption>
        <media xlink:href="EMMM-9-967-s002.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-sup-0003">
        <caption>
          <p>TableÂ EV2</p>
        </caption>
        <media xlink:href="EMMM-9-967-s003.doc">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-sup-0004">
        <caption>
          <p>TableÂ EV3</p>
        </caption>
        <media xlink:href="EMMM-9-967-s004.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Review Process File</p>
        </caption>
        <media xlink:href="EMMM-9-967-s012.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0001">
        <caption>
          <p>Source Data for FigureÂ 1</p>
        </caption>
        <media xlink:href="EMMM-9-967-s005.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0002">
        <caption>
          <p>Source Data for FigureÂ 3</p>
        </caption>
        <media xlink:href="EMMM-9-967-s006.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0003">
        <caption>
          <p>Source Data for FigureÂ 4</p>
        </caption>
        <media xlink:href="EMMM-9-967-s007.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0004">
        <caption>
          <p>Source Data for FigureÂ 5</p>
        </caption>
        <media xlink:href="EMMM-9-967-s008.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0005">
        <caption>
          <p>Source Data for FigureÂ 6</p>
        </caption>
        <media xlink:href="EMMM-9-967-s009.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0006">
        <caption>
          <p>Source Data for FigureÂ 7</p>
        </caption>
        <media xlink:href="EMMM-9-967-s010.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201607058-supp-data-0007">
        <caption>
          <p>Source Data for FigureÂ 8</p>
        </caption>
        <media xlink:href="EMMM-9-967-s011.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="emmm201607058-sec-0035">
      <title>Acknowledgements</title>
      <p>We are grateful to the patients and their clinicians and healthy volunteers for providing samples. Thanks to Stephan ZÃ¼chner for access to GEM.app software; to Heidi McBride and Richard J. Youle for reagents, Gyorgy Csordas, David M. Booth, Melanie Paillard, Valentina Debattisti, Tunde Golenar, and Gyorgy Bathori for helpful discussions; and to Gyorgyi Bathori, Marianna Marko, and Monika Sary for their technical help. This study was supported by the Hungarian Brain Research Program (KTIA_13_NAPâAâIII/6 to V.AâV.) and a Schizo2010 Consortium grant to M.M.J., an HAESF Senior Leadership Program Fellowship to A.G., and an NIH grant (DK51525) to G.H.</p>
    </ack>
    <ref-list content-type="cited-references" id="emmm201607058-bibl-0001">
      <title>References</title>
      <ref id="emmm201607058-bib-0001">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0001">
<string-name>
<surname>Bonifert</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Karle</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Tonagel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Batra</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wilhelm</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Theurer</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Schoenfeld</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kluba</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kamenisch</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Carelli</surname>
<given-names>V</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier</article-title>. <source>Brain</source>
<volume>137</volume>: <fpage>2164</fpage>â<lpage>2177</lpage>
<pub-id pub-id-type="pmid">24970096</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0002">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0002">
<string-name>
<surname>Chan</surname>
<given-names>DC</given-names>
</string-name> (<year>2006</year>) <article-title>Mitochondria: dynamic organelles in disease, aging, and development</article-title>. <source>Cell</source>
<volume>125</volume>: <fpage>1241</fpage>â<lpage>1252</lpage>
<pub-id pub-id-type="pmid">16814712</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0003">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0003">
<string-name>
<surname>Chauhan</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Raghava</surname>
<given-names>GP</given-names>
</string-name> (<year>2010</year>) <article-title>Prediction of GTP interacting residues, dipeptides and tripeptides in a protein from its evolutionary information</article-title>. <source>BMC Bioinformatics</source>
<volume>11</volume>: <fpage>301</fpage>
<pub-id pub-id-type="pmid">20525281</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0004">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0004">
<string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Vermulst</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>YE</given-names>
</string-name>, <string-name>
<surname>Chomyn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prolla</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>McCaffery</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>DC</given-names>
</string-name> (<year>2010</year>) <article-title>Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations</article-title>. <source>Cell</source>
<volume>141</volume>: <fpage>280</fpage>â<lpage>289</lpage>
<pub-id pub-id-type="pmid">20403324</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0005">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0005">
<string-name>
<surname>Chiara</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Castellaro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marin</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Petronilli</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Brusilow</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Juhaszova</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sollott</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Forte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bernardi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rasola</surname>
<given-names>A</given-names>
</string-name> (<year>2008</year>) <article-title>Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltageâdependent anion channels</article-title>. <source>PLoS ONE</source>
<volume>3</volume>: <fpage>e1852</fpage>
<pub-id pub-id-type="pmid">18350175</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0007">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0007">
<string-name>
<surname>Eisner</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lenaers</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hajnoczky</surname>
<given-names>G</given-names>
</string-name> (<year>2014</year>) <article-title>Mitochondrial fusion is frequent in skeletal muscle and supports excitationâcontraction coupling</article-title>. <source>J Cell Biol</source>
<volume>205</volume>: <fpage>179</fpage>â<lpage>195</lpage>
<pub-id pub-id-type="pmid">24751540</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0008">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0008">
<string-name>
<surname>Gurvitz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hartig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ruis</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>de Couet</surname>
<given-names>HG</given-names>
</string-name> (<year>2002</year>) <article-title>Preliminary characterisation of DML1, an essential Saccharomyces cerevisiae gene related to misato of <italic>Drosophila</italic> melanogaster</article-title>. <source>FEMS Yeast Res</source>
<volume>2</volume>: <fpage>123</fpage>â<lpage>135</lpage>
<pub-id pub-id-type="pmid">12702300</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0009">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0009">
<string-name>
<surname>Itoh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iijima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sesaki</surname>
<given-names>H</given-names>
</string-name> (<year>2013</year>) <article-title>Mitochondrial dynamics in neurodegeneration</article-title>. <source>Trends Cell Biol</source>
<volume>23</volume>: <fpage>64</fpage>â<lpage>71</lpage>
<pub-id pub-id-type="pmid">23159640</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0010">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0010">
<string-name>
<surname>Kimura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okano</surname>
<given-names>Y</given-names>
</string-name> (<year>2007</year>) <article-title>Human Misato regulates mitochondrial distribution and morphology</article-title>. <source>Exp Cell Res</source>
<volume>313</volume>: <fpage>1393</fpage>â<lpage>1404</lpage>
<pub-id pub-id-type="pmid">17349998</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0011">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0011">
<string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Handsaker</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wysoker</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fennell</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ruan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Homer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Marth</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Abecasis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Durbin</surname>
<given-names>R</given-names>
</string-name> (<year>2009</year>) <article-title>The sequence alignment/Map format and SAMtools</article-title>. <source>Bioinformatics</source>
<volume>25</volume>: <fpage>2078</fpage>â<lpage>2079</lpage>
<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0012">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0012">
<string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name> (<year>2011</year>) <article-title>A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data</article-title>. <source>Bioinformatics</source>
<volume>27</volume>: <fpage>2987</fpage>â<lpage>2993</lpage>
<pub-id pub-id-type="pmid">21903627</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0013">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0013">
<string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shirihai</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Hajnoczky</surname>
<given-names>G</given-names>
</string-name> (<year>2009</year>) <article-title>Mitochondrial âkissâandârunâ: interplay between mitochondrial motility and fusionâfission dynamics</article-title>. <source>EMBO J</source>
<volume>28</volume>: <fpage>3074</fpage>â<lpage>3089</lpage>
<pub-id pub-id-type="pmid">19745815</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0014">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0014">
<string-name>
<surname>Loson</surname>
<given-names>OC</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>DC</given-names>
</string-name> (<year>2013</year>) <article-title>Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission</article-title>. <source>Mol Biol Cell</source>
<volume>24</volume>: <fpage>659</fpage>â<lpage>667</lpage>
<pub-id pub-id-type="pmid">23283981</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0015">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0015">
<string-name>
<surname>Meeusen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>DeVay</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Block</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>CassidyâStone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wayson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McCaffery</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Nunnari</surname>
<given-names>J</given-names>
</string-name> (<year>2006</year>) <article-title>Mitochondrial innerâmembrane fusion and crista maintenance requires the dynaminârelated GTPase Mgm1</article-title>. <source>Cell</source>
<volume>127</volume>: <fpage>383</fpage>â<lpage>395</lpage>
<pub-id pub-id-type="pmid">17055438</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0016">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0016">
<string-name>
<surname>Miklos</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Burns</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Maleszka</surname>
<given-names>R</given-names>
</string-name> (<year>1997</year>) <article-title>An essential cell division gene of <italic>Drosophila</italic>, absent from Saccharomyces, encodes an unusual protein with tubulinâlike and myosinâlike peptide motifs</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>94</volume>: <fpage>5189</fpage>â<lpage>5194</lpage>
<pub-id pub-id-type="pmid">9144213</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0017">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0017">
<string-name>
<surname>Molnar</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bencsik</surname>
<given-names>P</given-names>
</string-name> (<year>2006</year>) <article-title>Establishing a neurologicalâpsychiatric biobank: banking, informatics, ethics</article-title>. <source>Cell Immunol</source>
<volume>244</volume>: <fpage>101</fpage>â<lpage>104</lpage>
<pub-id pub-id-type="pmid">17448454</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0018">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0018">
<string-name>
<surname>MottierâPavie</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cenci</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Verni</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gatti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bonaccorsi</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>) <article-title>Phenotypic analysis of misato function reveals roles of noncentrosomal microtubules in <italic>Drosophila</italic> spindle formation</article-title>. <source>J Cell Sci</source>
<volume>124</volume>: <fpage>706</fpage>â<lpage>717</lpage>
<pub-id pub-id-type="pmid">21285248</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0019">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0019">
<string-name>
<surname>Nguyen</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lewandowska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maxfield</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schuler</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Macfarlane</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Saunders</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>CA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Loss of Miro1âdirected mitochondrial movement results in a novel murine model for neuron disease</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>111</volume>: <fpage>E3631</fpage>â<lpage>E3640</lpage>
<pub-id pub-id-type="pmid">25136135</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0020">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0020">
<string-name>
<surname>Ono</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Isobe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakada</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>JI</given-names>
</string-name> (<year>2001</year>) <article-title>Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria</article-title>. <source>Nat Genet</source>
<volume>28</volume>: <fpage>272</fpage>â<lpage>275</lpage>
<pub-id pub-id-type="pmid">11431699</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0021">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0021">
<string-name>
<surname>Otera</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cleland</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Setoguchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yokota</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Mihara</surname>
<given-names>K</given-names>
</string-name> (<year>2010</year>) <article-title>Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells</article-title>. <source>J Cell Biol</source>
<volume>191</volume>: <fpage>1141</fpage>â<lpage>1158</lpage>
<pub-id pub-id-type="pmid">21149567</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0022">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0022">
<string-name>
<surname>Partikian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Olveczky</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Swaminathan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Verkman</surname>
<given-names>AS</given-names>
</string-name> (<year>1998</year>) <article-title>Rapid diffusion of green fluorescent protein in the mitochondrial matrix</article-title>. <source>J Cell Biol</source>
<volume>140</volume>: <fpage>821</fpage>â<lpage>829</lpage>
<pub-id pub-id-type="pmid">9472034</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0023">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0023">
<string-name>
<surname>Richards</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aziz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bale</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bick</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Das</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>GastierâFoster</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grody</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>Hegde</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lyon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Spector</surname>
<given-names>E</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. <source>Genet Med</source>
<volume>17</volume>: <fpage>405</fpage>â<lpage>424</lpage>
<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0024">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0024">
<string-name>
<surname>Song</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Ghochani</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McCaffery</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Frey</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>DC</given-names>
</string-name> (<year>2009</year>) <article-title>Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion</article-title>. <source>Mol Biol Cell</source>
<volume>20</volume>: <fpage>3525</fpage>â<lpage>3532</lpage>
<pub-id pub-id-type="pmid">19477917</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0025">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0025">
<string-name>
<surname>Spiegel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Saada</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Flannery</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Burte</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Soiferman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Khayat</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eisner</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vladovski</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Bindoff</surname>
<given-names>LA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2016</year>) <article-title>Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation</article-title>. <source>J Med Genet</source>
<volume>53</volume>: <fpage>127</fpage>â<lpage>131</lpage>
<pub-id pub-id-type="pmid">26561570</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0026">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0026">
<string-name>
<surname>Suomalainen</surname>
<given-names>A</given-names>
</string-name> (<year>2015</year>) <article-title>Mitochondrial roles in disease: a box full of surprises</article-title>. <source>EMBO Mol Med</source>
<volume>7</volume>: <fpage>1245</fpage>â<lpage>1247</lpage>
<pub-id pub-id-type="pmid">26194910</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0027">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0027">
<string-name>
<surname>Twig</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liesa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wikstrom</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Molina</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Las</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Yaniv</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hajnoczky</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Shirihai</surname>
<given-names>OS</given-names>
</string-name> (<year>2010</year>) <article-title>Biophysical properties of mitochondrial fusion eventsÂ in pancreatic betaâcells and cardiac cells unravel potential control mechanisms of its selectivity</article-title>. <source>Am J Physiol Cell Physiol</source>
<volume>299</volume>: <fpage>C477</fpage>â<lpage>C487</lpage>
<pub-id pub-id-type="pmid">20445168</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0028">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0028">
<string-name>
<surname>Tyynismaa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ylikallio</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Molnar</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Haller</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Suomalainen</surname>
<given-names>A</given-names>
</string-name> (<year>2009</year>) <article-title>A heterozygous truncating mutation in RRM2B causes autosomalâdominant progressive external ophthalmoplegia with multiple mtDNA deletions</article-title>. <source>Am J Hum Genet</source>
<volume>85</volume>: <fpage>290</fpage>â<lpage>295</lpage>
<pub-id pub-id-type="pmid">19664747</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0029">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0029">
<string-name>
<surname>Wang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hakonarson</surname>
<given-names>H</given-names>
</string-name> (<year>2010</year>) <article-title>ANNOVAR: functional annotation of genetic variants from highâthroughput sequencing data</article-title>. <source>Nucleic Acids Res</source>
<volume>38</volume>: <fpage>e164</fpage>
<pub-id pub-id-type="pmid">20601685</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0030">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0030">
<string-name>
<surname>Weaver</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Eisner</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Varnai</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hunyady</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hajnoczky</surname>
<given-names>G</given-names>
</string-name> (<year>2014</year>) <article-title>Distribution and apoptotic function of outer membrane proteins depend on mitochondrial fusion</article-title>. <source>Mol Cell</source>
<volume>54</volume>: <fpage>870</fpage>â<lpage>878</lpage>
<pub-id pub-id-type="pmid">24813948</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201607058-bib-0031">
        <mixed-citation publication-type="journal" id="emmm201607058-cit-0031">
<string-name>
<surname>Willis</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Kaufmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>van Delft</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Czabotar</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Ierino</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Fairlie</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Bouillet</surname>
<given-names>P</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2007</year>) <article-title>Apoptosis initiated when BH3 ligands engage multiple Bclâ2 homologs, not Bax or Bak</article-title>. <source>Science</source>
<volume>315</volume>: <fpage>856</fpage>â<lpage>859</lpage>
<pub-id pub-id-type="pmid">17289999</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>